Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Trial Profile

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2014

At a glance

  • Drugs Rasagiline (Primary) ; Pramipexole
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms ACTOR
  • Most Recent Events

    • 21 Jun 2012 Results presented at the 16th International Congress of Parkinson's Disease and Movement Disorders.
    • 25 May 2012 Actual patient number is 112 as reported by ClinicalTrials.gov.
    • 25 May 2012 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top